News

To identify selectively interacting proteins of a drug molecule, it is coupled to caprotec’s Capture Compound scaffold and incubated with human cell lysates, subcellular fractions or whole cells.

Remoxy, being developed by King Pharmaceuticals, is a painkiller with a formulation designed to reduce potential risks of unintended use. Apart from this drug, King Pharmaceuticals is also

As per the terms of the agreement GSK is expected to fully fund and be responsible for all clinical and regulatory development. Additionally, GSK is also expected to

Merck said that the Louisiana case is the first Vioxx lawsuit brought by a state attorney general to go to trial. The case was filed by the Louisiana

Dr Morrissey will replace George Scangos, who has resigned to become president and CEO of Biogen Idec. Dr Morrissey is currently working as a president of research and

The payment triggers Boehringer Ingelheim’s recent advancement of a small molecule inhibitor of 11beta-HSD-1 into Phase I clinical trials. Vitae Pharma’s 11beta-hydroxysteroid dehydrogenase (HSD)-1 is targeted for the

Muparfostat is a multi-targeted cancer therapeutic in late stage development which inhibits both angiogenesis (or tumour promoting) factors such as Vascular Endothelial Growth Factor (VEGF), Fibroblast Growth Factors

The issued patent covers methods of inhibiting the spread of cancer in patients using phosphoinositide-3-kinase (PI3K) inhibitors alone or in combination with chemotherapeutic agents. The phosphatidylinositol 3-kinase (PI3K)

AstraZeneca said that the court held the ‘314 patent to be non-obvious and properly reissued and it also found that no inequitable conduct was committed by any Shionogi